Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: Future FTSE +0.02%, DAX +0.28%, CAC40 +0.21%

Jun 25 ,2025

  • Synopsis

    • European equity markets are set for a positive open amidst advancing Asian equities Wednesday. Greater China markets outperforming with property developers leading in Hong Kong. Semis driving Taiwan towards highest since March. Japan, Australia and Korea flat. S&P 500 futures unchanged afterhours.

    • Geopolitical tensions tamping down with Iran-Israel ceasefire holding, pulling crude back below pre-war levels. Attention shifting back to prospect of negotiations after Iran's president said willing to return to talks. White House also pushed back against media reports citing preliminary intelligence assessment that US strikes dealt limited damage to Iran's underground nuclear facilities and likely set back program by only few months.

    • In UK, weekly PMQs at 12noon BST with committee topics including spending review 2025 at 10:00BST (Chief Secretary to the Treasury Jones) and cost of energy 15:00 (Ofgem CEO Brearley). Politico hosts "The EU's budget reset: Will the energy transition get its fair share?". FT and The Banker joint event at 14:00BST The State of Banking in 2025 is in the in the lead-up to the Global Banking Summit 2025. European Automobile Manufacturers' Association (ACEA) May new passenger car registrations for EU + EFTA + UK.

    • On the central bank front, Riksbank minutes from last MPC meeting published at 9:30CET whilst ECB publishes Macroprudential Bulletin at 11:00CET. SNB releases latest quarterly bulletin at 15:00CET. Slovak central bank publishes latest report on economic and monetary developments and Czech central bank interest rate decision. Bundesbank's Mauderer speech at 10:00CET at London Climate Action Week (Sat (21st)-Sun (29th), main program, all events) as well as panellist at 16:00 at related event at the German Embassy in London. At Almedalen Week, Riksbank's Bunge participates at 11:00CET in a seminar on economic developments in Sweden and the world organized by Skandia and on payments and preparedness at 16:00 organized by Kontantupproret and Thedéen participates at 16:45 in a debate about the economic situation and the latest interest rate decision on Dagens Industri's stage. CCBS 'Transforming monetary policy' conf (through Thu), Riksbank's Breman speech 13:30BST, BOE's Lombardelli, Pill, Rosen and Greene chair sessions/speak over the two days. ECB's Donnery speech/Q&A at 19:30CET at SSM-Senior Forum.

    • A light earnings front see Kapsch TrafficCom (KTCG.AV) reporting FY EPS (€0.48) and Gabriel Holding (GABR.DC) raised FY revenue and EBIT guidance to revenue DKK 490-520M vs prior DKK485-530M and EBIT DKK 25-35M vs prior DKK20-30M

  • Politics/Macro/World News

    • EU prepares €95B retaliatory tariff threat on the US ahead 9-Jul deadline nears:

    • Iran-Israel ceasefire holding, Iranians say they are ready for diplomacy:

    • Central banks eyeing further diversification of FX reserves away from dollar after Liberation Day tariffs:

  • Top company news

    • Earnings

      • GABR.DC (Gabriel Holding) -- raises FY revenue and EBIT guidance: Rev DKK 490-520M vs prior DKK485-530M. EBIT DKK 25-35M vs prior DKK20-30M

      • KTCG.AV (Kapsch TrafficCom) -- reports FY EPS (€0.48) and unclear if comparable to FactSet €0.04 [2 est, €0.03-0.05]

    • M&A

      • MCAP.SS (MedCap) -- 's Unimedic Pharma AB acquires XGX Pharma ApS in Denmark for an initial cash payment of DKK135M for 100% of the company's shares plus potential additional payment of up to DKK140M

      • RI.FP (Pernod Ricard) -- Suntory interested in acquiring Imperial Blue whiskey brand from Pernod Ricard - Economic Times (00:52 IST / 03:52 JST / 21:52 CEST)

      • ILTY.IM (illimity Bank) -- Banca Ifis will pay additional consideration of €0.1775/share in cash for each illimity Bank share tendered to offer in case acceptances higher than 90%

      • RGLS (Regulus Therapeutics) -- Novartis announces expiration of Regulus Therapeutics tender offer

      • SAB.SM (Banco de Sabadell) -- Banco Sabadell informs on the Council of Ministers' authorization of the economic concentration resulting from the offer, subject to an additional condition to those commitments already submitted by BBVA

      • COPN.SW (Cosmo Pharmaceuticals) -- to sell "Digital Trust" to its existing customer Tinexta InfoCert

      • IPS.FP (Ipsos) -- completes acquisition of The BVA Family

      • EFGN.SW (EFG International) -- EFG International's subsidiary Shaw and Partners to acquire a 75% stake in New Zealand-based Investment Services Group for NZ$67.5M (approx. CHF 32.4M)

      • GIMB.BB (Gimv) -- acquires a majority stake in Alpine' price not disclosed

    • Healthcare

      • REGN (Regeneron) -- TD Cowen comments on Regeneron matching program, copay support for anti-VEGF treatments

      • SAN.FP (Sanofi) -- Sanofi's Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation

      • SRPT (Sarepta Therapeutics) -- FDA investigating deaths due to acute liver failure in non-ambulatory Duchenne Muscular Dystrophy patients following treatment with Sarepta Therapeutics' ELEVIDYS

      • INDV.LN (Indivior) -- appoints Tony Kingsley to the board, supported by affiliates of Oaktree Capital Management

      • GALD.SW (Galderma Group) -- initiates two new clinical trials investigating nemolizumab in patients with systemic sclerosis and chronic pruritus of unknown origin

      • CYAD.BB (Celyad Oncology) -- conducting strategic review

      • FYB.GR (Formycon) -- notes Valorum Biologics becomes commercialization partner for Eylea biosimilar FYB203/AHZANTIVE (aflibercept-mrbb) in US and Canada

    • Other

      • IDIA.SW (Idorsia) -- launches repurchase offer for its 2025 and 2028 convertible bonds

      • EVT.GR (Evotec) -- joins NURTuRE-AKI consortium to gain multi-omics-based molecular understanding of acute kidney injury

      • NDX1.GR (Nordex) -- receives orders from UKA for a total of 64 wind turbines totaling 435 MW in Germany; orders are part of an existing framework agreement

      • DONE.SS (Done.ai Group AB) -- initiates evaluation of incorporating blockchain infrastructure, including a NOK 20M Bitcoin allocation

      • SAN.SM (Banco Santander) -- announces tender for up to €1.5B 4.375% CoCo securities; intends to issue a new series of contingent convertible perpetual preferred securities

      • PUM.GR (Puma) -- issues Q2 Aide Memoire; no new information is provided

      • DG.FP (VINCI SA) -- VINCI implements share buyback program

      • AVOL.SW (Avolta) -- awarded duty-free tender at Santiago de Chile International Airport

      • KEMIRA.FH (Kemira) -- and Bluepha announce exclusive partnership to commercialize fully biobased barrier coatings in APAC

      • AML.LN (Aston Martin Lagonda Global Holdings) -- After three-month halt, Aston Martin to resume exports to US - London Times

      • EU retaliatory tariffs on US imports could include Boeing aircraft -- Bloomberg

      • European Automobile Manufacturers' Association (ACEA) May new passenger car registrations for EU + EFTA + UK +1.9% y/y

  • Key rating changes

    • Upgrades

      • CLARI.FP (Clariane) -- to outperform from neutral at Oddo

      • AKE.FP (Arkema) -- to neutral from underweight at JPMorgan

      • BFSA.GR (Befesa) -- to overweight from equal-weight at Morgan Stanley

      • HPOL.B.SS (HEXPOL) -- to buy from hold at SEB

      • SBS.GR (Stratec) -- to buy from hold at Kepler Cheuvreux

      • STLAP.FP (Stellantis) -- to buy at Jefferies

      • SWEC.B.SS (Sweco) -- to buy from hold at Pareto (earlier, timing uncertain)

    • Downgrades

      • AKRBP.NO (Aker BP) -- to hold from buy at ABG Sundal Collier

      • OKEA.NO (Okea) -- to hold from buy at ABG Sundal Collier

      • SKA.B.SS (Skanska) -- to hold from buy at Handelsbanken

      • KOG.NO (Kongsberg Gruppen) -- to sell from hold at Pareto

      • HBH.GR (Hornbach Holding) -- to hold from buy at Berenberg

    • Initiations

      • RANA.NO (Rana Gruber) -- buy at ABG Sundal Collier

      • JMAT.LN (Johnson Matthey) -- hold at Kepler Cheuvreux

      • YUBICO.SS (Yubico) -- hold at Pareto

  • Data

    • Nikkei +0.30% to 38907.37

    • Hang Seng +0.83% to 24377.34

    • Shanghai Composite +0.41% to 3434.72

    • S&P futures +2.5 vs prior close of 6146.3

    • €-$ +0.0009 or +0.08% to 1.1620

    • $-¥ +0.12 or +0.08% to 145.05

    • €-¥ +0.28 or +0.17% to 168.52

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE